Management of advanced mycosis fungoides and Sézary Syndrome: International Recommendations for systemic treatments and allogeneic hematopoietic cell transplantation from the European Hematology Association, the EORTC Cutaneous Lymphoma Tumours Group, the International Society for Cutaneous Lymphoma, and the Lymphoma Working Party of the EBMT
HemaSphere · 2026-11 · 10 (11)
DOI: 10.1002/hem3.70505 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 05.11.2026. Verfasst von Francesco Onida und 29 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and BMT Unit, ASST Fatebenefratelli-Sacco Milan Italy. Die Arbeit nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are the most aggressive forms of cutaneous T‐cell lymphoma and remain associated with a poor prognosis and heterogeneous therapeutic approaches. Recent advances, including targeted therapies and improved transplant strategies, have substantially expanded treatment options, highlighting the need for updated international guidance integrating dermatologic, hematologic, and transplant perspectives. An international multidisciplinary panel convened by the European Hematology Association (EHA), the EORTC Cutaneous Lymphoma Tumours Group (EORTC‐CLTG), the International Society for Cutaneous Lymphoma (ISCL), and the EBMT Lymphoma Working Party reviewed the available evidence and developed consensus recommendations for the management of advanced MF and SS. Thirty international experts participated in the process. Recommendations address diagnostic work‐up, systemic therapies, treatment sequencing, combination strategies, and indications for allogeneic hematopoietic cell transplantation (allo‐HCT). The consensus supports a stage‐adapted and compartment‐oriented therapeutic approach. Immunomodulatory strategies remain central in advanced CTCL: extracorporeal photopheresis is commonly used as first‐line therapy in SS and in patients with significant blood involvement, while interferon‐α and retinoids are widely used in MF, often in combination with skin‐directed therapies. Mogamulizumab and brentuximab vedotin represent key options after prior systemic therapy, with differential activity across skin, blood, and nodal compartments. Combination approaches integrating systemic and skin‐directed treatments may improve response depth and durability. Practical treatment algorithms for advanced MF and SS are proposed to support therapeutic sequencing and multidisciplinary management. Allo‐HCT remains the only potentially curative treatment and should be considered early in selected patients with high‐risk disease features.
Autor:innen und Institutionen
- Hematology and BMT Unit, ASST Fatebenefratelli-Sacco Milan Italy.
- Department of Oncology and Hemato-Oncology University of Milan Milan Italy.
- Department of Medical Sciences Dermatologic Clinic, University of Turin Turin Italy.
- Department of Dermatology University Hospitals Birmingham and Department of Immunology and Immunotherapy University of Birmingham UK.
- Clinical Hematology Department Institut Català d'Oncologia-Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona Barcelona Spain.
- Cutaneous Lymphoma Service, Davidoff Cancer Centre, Rabin Medical Center, Gray Faculty of Medicinal and Health Sciences, Tel Aviv University Tel Aviv Israel.
ORCID-Profile: Francesco Onida, Pietro Quaglino, Anna Sureda, Evangelia Papadavid, Silvia Alberti-Violetti, Martine Bagot, Amrita Goyal-O'Leary, Rudolf Stadler, Rein Willemze, Marco Ardigò, Emilio Berti, Francine Foss, Pablo Ortiz-Romero, Alessandro Pileri, Pierluigi Porcu, Henry M Prince, Sima Rozati, Maarten H Vermeer, Pier Luigi Zinzani
Zitieren
APA
Onida, F., Quaglino, P., Scarisbrick, J., Sureda, A., Hodak, E., Papadavid, E., Alberti-Violetti, S., Bagot, M., Cerroni, L., Goyal-O'Leary, A., Stadler, R., Willemze, R., Zain, J., Ardigò, M., Berti, E., de Masson, A., Duarte, R. F., Foss, F., González-Barca, E., …, & Zinzani, P. L. (2026). Management of advanced mycosis fungoides and Sézary Syndrome: International Recommendations for systemic treatments and allogeneic hematopoietic cell transplantation from the European Hematology Association, the EORTC Cutaneous Lymphoma Tumours Group, the International Society for Cutaneous Lymphoma, and the Lymphoma Working Party of the EBMT. HemaSphere, 10(11). https://doi.org/10.1002/hem3.70505
Vancouver
Onida F, Quaglino P, Scarisbrick J, Sureda A, Hodak E, Papadavid E, et al. Management of advanced mycosis fungoides and Sézary Syndrome: International Recommendations for systemic treatments and allogeneic hematopoietic cell transplantation from the European Hematology Association, the EORTC Cutaneous Lymphoma Tumours Group, the International Society for Cutaneous Lymphoma, and the Lymphoma Working Party of the EBMT. HemaSphere. 2026;10(11). doi:10.1002/hem3.70505
BibTeX
@article{Onida2026,
author = {Onida, Francesco and Quaglino, Pietro and Scarisbrick, Julia and Sureda, Anna and Hodak, Emmilia and Papadavid, Evangelia and Alberti-Violetti, Silvia and Bagot, Martine and Cerroni, Lorenzo and Goyal-O'Leary, Amrita and Stadler, Rudolf and Willemze, Rein and Zain, Jasmine and Ardigò, Marco and Berti, Emilio and de Masson, Adèle and Duarte, Rafael F and Foss, Francine and González-Barca, Eva and Guitart, Joan and Ortiz-Romero, Pablo and Pileri, Alessandro and Porcu, Pierluigi and Prince, Henry M and Rozati, Sima and Rupoli, Serena and Vermeer, Maarten H and Whittaker, Sean and Pimpinelli, Nicola and Zinzani, Pier Luigi},
title = {Management of advanced mycosis fungoides and Sézary Syndrome: International Recommendations for systemic treatments and allogeneic hematopoietic cell transplantation from the European Hematology Association, the EORTC Cutaneous Lymphoma Tumours Group, the International Society for Cutaneous Lymphoma, and the Lymphoma Working Party of the EBMT},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {11},
doi = {10.1002/hem3.70505}
}
EUVIMED